Nabriva Therapeutics PLC reports results for the quarter ended in December - Earnings Summary

Nabriva Therapeutics

29/03/2022 22:54

* Nabriva Therapeutics PLC  NBRV.OQ  reported a quarterly
adjusted
loss of 24 cents​​ per share for the quarter ended in December.
The mean expectation of two analysts for the quarter was for a
loss of 19 cents per share.
    * Revenue rose 276.5% to $9.26 million from a year ago; 
analysts
expected $10.10 million. 
    * Nabriva Therapeutics PLC's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Nabriva Therapeutics PLC shares had fallen by 21.0% this
quarter.
    * The company reported a quarterly loss of $13.06 million.
    * Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $2.68 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 29 at 09:53 p.m.  ​All
figures in US dollars unless otherwise stated